Table 1 Descriptive data and outcomes of patients.
Parameters | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
MS (n = 235) | Non-MS (n = 1246) | P | MS (n = 235) | Non-MS (n = 928) | P | |
Gender, n (male%) | 155 (66.0) | 706 (56.7) | 0.008* | 155 (66.0) | 626 (66.6) | 0.853 |
Age, y | 62.8 ± 10.0 | 59.9 ± 12.5 | 0.001* | 62.8 ± 10.0 | 60.9 ± 11.7 | 0.023* |
ASA | < 0.001* | < 0.001* | ||||
I, n (%) | 0 (0.0) | 434 (34.8) | 0 (0.0) | 304 (32.3) | ||
II, n (%) | 91 (38.7) | 519 (41.7) | 91 (38.7) | 408 (43.4) | ||
III, n (%) | 134 (57.0) | 293 (23.5) | 134 (57.0) | 228 (24.3) | ||
IV, n (%) | 10 (4.3) | 0 (0.0) | 10 (4.3) | 0 (0.0) | ||
Operation time, h | 3.0 ± 0.9 | 2.8 ± 1.0 | 0.003* | 3.0 ± 0.9 | 2.9 ± 1.0 | 0.132 |
Chemotherapy, n (%) | 6 (2.6) | 32 (2.6) | 0.989 | 6 (2.6) | 20 (2.1) | 0.692 |
Biliary stented, n (%) | 21 (8.9) | 116 (9.3) | 0.856 | 21 (8.9) | 84 (8.9) | 1.000 |
Blood transfusion, n (%) | 48 (20.4) | 264 (21.2) | 0.793 | 48 (20.4) | 213 (22.7) | 0.461 |
Operation method | 0.006* | 0.854 | ||||
PD, n (%) | 156 (66.4) | 707 (56.7) | 156 (66.4) | 618 (65.7) | ||
PP, n (%) | 79 (33.6) | 539 (43.3) | 79 (33.6) | 322 (34.3) | ||
BMI, kg/m2 | 25.6 ± 2.7 | 22.4 ± 2.9 | < 0.001* | 25.6 ± 2.7 | 22.3 ± 2.9 | < 0.001* |
Diagnosis of MS | ||||||
Hypertension, n (%) | 182 (77.4) | 237 (19.0) | < 0.001* | 182 (77.4) | 181 (19.3) | < 0.001* |
Hyperlipidemia, n (%) | 198 (84.3) | 394 (31.6) | < 0.001* | 198 (84.3) | 323 (34.4) | < 0.001* |
Obesity, n (%) | 157 (66.8) | 202 (16.2) | < 0.001* | 157 (66.8) | 146 (15.5) | < 0.001* |
Diabetes, n (%) | 197 (83.8) | 426 (34.2) | < 0.001* | 197 (83.8) | 337 (35.9) | < 0.001* |
Total length of stay, d | 14 (10.21) | 13 (10.18) | 0.001* | 14 (10.21) | 13 (10.19) | 0.083 |
Clavien-Dindo grades | 0.052 | 0.274 | ||||
0, n (%) | 171 (72.7) | 971 (77.9) | 171 (72.7) | 692 (74.6) | ||
I, n (%) | 29 (12.3) | 119 (9.5) | 29 (12.3) | 104 (11.2) | ||
II, n (%) | 31 (13.2) | 122 (9.8) | 31 (13.2) | 105 (11.3) | ||
III, n (%) | 2 (0.9) | 20 (1.6) | 2 (0.9) | 15 (1.6) | ||
IV, n (%) | 0 (0.0) | 12 (1.0) | 0 (0.0) | 10 (1.1) | ||
V, n (%) | 2 (0.9) | 2 (0.2) | 2 (0.9) | 2 (0.2) | ||
ICU treatment days, d | 2 (0.4) | 2 (0.3) | 0.056 | 2 (0.4) | 2 (0.3) | 0.150 |
Outcomes in 30 days | 1.000 | |||||
Death, n (%) | 2 (0.9) | 8 (0.6) | 2 (0.9) | 8 (0.9) | ||
Survival, n (%) | 233 (99.1) | 1238 (99.4) | 233 (99.1) | 932 (99.1) | ||
Outcomes in 90 days | 0.210 | 0.341 | ||||
Death, n (%) | 5 (2.1) | 14 (1.1) | 5 (2.1) | 14 (1.5) | ||
Survival, n (%) | 230 (97.9) | 1232 (98.9) | 230 (97.9) | 926 (98.5) | ||
